This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Seeking Clues to Astrazeneca (AZN) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2024.
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
by Kinjel Shah
SNY and RHHBY announce fourth-quarter earnings. NVO's novel obesity medicine, amycretin, shows superior weight loss in study.
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
by Zacks Equity Research
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $70.25, representing a +0.95% change from its previous close.
Should AstraZeneca Stock Be in Your Portfolio Pre-Q4 Earnings?
by Zacks Equity Research
AZN's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected to have driven the company's top line.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
by Zacks Equity Research
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication
by Zacks Equity Research
The FDA approves AstraZeneca's sBLA for Enhertu to treat HER2-low or HER2-ultralow metastatic breast cancer in the United States.
Merck Q4 Earnings Coming Up: Buy, Hold or Sell MRK Stock Now?
by Kinjel Shah
When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, Keytruda.
Pharma Stock Roundup: JNJ's Q4 Earnings, FDA Nod to AZN, Daiichi Drug
by Kinjel Shah
J&J announces Q4 earnings. FDA approves AZN and Daiichi's Dato-DXd for breast cancer.
Here's Why Astrazeneca (AZN) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer
by Zacks Equity Research
The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs chemotherapy in certain breast cancer patients.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
by Kinjel Shah
J&J offers to buy ITCI for $14.6 billion. LLY announces disappointing preliminary sales numbers for the fourth quarter.
Why Astrazeneca (AZN) is a Top Value Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $66.58, representing a -0.09% change from its previous close.
Why Astrazeneca (AZN) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Sanofi Down 10% in 3 Months: How Should You Play the Stock?
by Kinjel Shah
SNY's reasonable valuation, improving top-line performance, contributions from new product launches and positive pipeline progress are good enough reasons to stay invested in the stock
AstraZeneca Stock Down Almost 14% in 3 Months: Time to Sell?
by Kinjel Shah
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales. It has several candidates with blockbuster potential.
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
by Zacks Equity Research
Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer are included in this Analyst Blog.
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
by Zacks Equity Research
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
5 Large Drug Stocks to Keep An Eye On in the New Year
by Kinjel Shah
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.
Astrazeneca (AZN) Stock Moves -0.39%: What You Should Know
by Zacks Equity Research
The latest trading day saw Astrazeneca (AZN) settling at $66.26, representing a -0.39% change from its previous close.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Emergent Stock Skyrockets 251% YTD: How to Play the Stock?
by Sundeep Ganoria
The appointment of CEO John Papa earlier this year has been a key driver of EBS' strong performance, sparking significant investor optimism.